The placental drug Melsmon® is effective for correction of insomnia and other climacteric symptoms in premenopausal women. Decrease of MMI is shown both in groups with Melsmon® and Placebo, but it was more significant in patients who used Melsmon®.
There were 40 women under the observation, with mild and moderate symptoms of climacteric syndrome with sleep disorders (for that the investigators evaluated modified Kupperman Index). All patients were randomized with the help of the envelope method with the allocation ratio of 1:1 (one-to-one). 20 women were prescribed placenta extract Melsmon and 20 received placebo during 4 months.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
40
Scientific Center for Family Health and Human Reproduction Problems, Russia
Irkutsk, Russia
Treatment-Related Changes of Kupperman Index
kupperman index scale (score)
Time frame: 4 months after the treatment
Treatment-Related Changes of Menstrual Function
ultrasound assessment of endometrium growth (mm)
Time frame: 4 months after the treatment
Treatment-Related Changes of Depression Symptoms
kupperman index questionnaire (score)
Time frame: 4 months after the treatment
Treatment-Related Improvement in Skin Conditions
the questionnaire developed by the investigators (score)
Time frame: 4 months after the treatment
Treatment-Related Changes of Sleep Quality
Pittsburgh Sleep Quality Index (score)
Time frame: 4 months after the treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.